How can femtech enhance women's special journey to delivery? How can it help them start that journey when they're having difficulties in conceiving? A common understatement that you may hear these days is that the world has been affected by the Pandemic. Let's get something straight, the world has not merely been "affected" by the Pandemic, it has completely transformed, or let's say, tele-transformed. The Pandemic has had an obscene amount of negative consequences on the world, yet, dare we say it, there are a few players that have somewhat benefitted from the situation, players that encourage and believe in virtual, digitally-powered transactions.

The partnership between Sensyne Health and Microsoft will entail the aim of improving, augmenting, and reducing the cost of patient care. Expected to deliver latest generation healthcare'cloud-first' systems and predictive machine learning algorithms, while reducing demand on global health systems and increasing scalability of care, the agreement includes the following aspects: Sensyne's AI healthcare expertise will be combined with Micosoft's latest healthcare capabilities. These include clinical workflow and patient engagement tool Health Cloud, digital waiting room and remote consultation service Virtual Consult, and natural language interaction system Health Bot. Richard Farrell, chief innovation officer at Netcall, explores how healthcare can undergo effective digital transformation one step at a time. "This strategic partnership with Microsoft will further enhance Sensyne's ability to advance and scale the benefits that advanced clinical AI can bring to improve patient outcomes and accelerate the development of new medicines through its research partnerships with NHS Trusts," said Lord Paul Drayson, CEO of Sensyne Health.

Lord Drayson seems a man on the move. As an amateur racing driver, it is perhaps an innate charateristic, and in the current debate around health data his foot is very much on the gas. I meet the former Labour government science and defence minister shortly after he lays out a bold new vision for the NHS at FutureScot's recent Digital Health & Care conference in Glasgow. Urbane and well-connected, Drayson is also a keen student of policy and how the arguments around big tech and health data are shaping up. For background, there is an intensifying argument that the NHS needs to make much more use of a still largely untapped goldmine of data, which could herald a new dawn in the way we diagnose, treat and manage disease – not to mention save billions of pounds annually.

Artificial intelligence has been embraced for its ability to offer insight from big data. By applying the technology to genetics, a research team led by Queen Mary University of London has found clues that they say could aid the development of new drugs for heart failure and identify people at risk of the disease. Based on an AI analysis of heart MRI images from 17,000 volunteers in UK Biobank, the researchers linked genetic factors to 22% to 39% of abnormalities in the size and function of the heart's left ventricle, which pumps blood into the aorta. They published the findings in the journal Circulation. The team identified or confirmed 14 regions in the human genome that play a part in determining the size and function of the left ventricle, because they contain genes that regulate the early development of heart chambers and the contraction of heart muscle.

Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announces that it has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health's proprietary clinical AI technology platform. The initial agreement will generate revenues for Sensyne Health of £5 million across the two-year collaboration. Sensyne Health's partner NHS trusts will receive a 4% share of all revenues generated by Sensyne Health under this collaboration. This will be in addition to the NHS Trust's existing shareholdings in Sensyne Health plc. The NHS Long Term Plan identifies cardiovascular disease as a clinical priority and the leading condition where lives can be saved by the NHS over the next 10 years.

Sensyne Health, a British artificial intelligence technology company, has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health's proprietary clinical AI technology platform. The initial agreement will generate revenue for Sensyne Health of £5 million across the two-year collaboration. Sensyne Health's partner National Health Service trusts will receive a 4% share of all revenue generated by Sensyne Health under this collaboration. This will be in addition to the NHS Trust's existing shareholdings in Sensyne Health. The NHS Long Term Plan identifies cardiovascular disease as a clinical priority and the leading condition where lives can be saved by the NHS over the next 10 years.

Healthcare technology company Sensyne Health has signed Strategic Research Agreements (SRA) with Wye Valley and George Eliot Hospital NHS Trusts. The agreements will allow Sensyne Health to analyse anonymised patient data using clinical artificial intelligence (Clinical AI) technology. The purpose of the research is to derive new insights that will improve the care of NHS Trusts' patients and help to find new treatments. Both Trusts will receive a £2.5 million equity stake in Sensyne Health (at a price of £1.75 per share) and will also benefit from royalties that arise from any discoveries. The royalties the Trust receives will be reinvested back into the NHS which can fund further research and can help deliver higher quality patient care at lower cost.